Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?
View original at finance.yahoo.comMerck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? A month has gone by since the last earnings report for Merck (MRK). Shares have added about 1.7% in that time frame, outperforming the S&P 500…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Merck has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months
80% confidenceRoche Holding has a Zacks Rank #3 (Hold)
80% confidenceGeneric competition for Januvia/Janumet, Bridion and Dificid is expected to hurt revenues by approximately $2.5 billion in 2026
80% confidenceA lower-than-expected infant immunization rate and high inventory levels in the market hurt Enflonsia sales in Q4 2025
80% confidenceMerck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s
80% confidenceKeytruda growth was negatively impacted by approximately $200 million due to the unfavorable timing of wholesaler purchases in the United States in Q4 2025
80% confidenceAdjusted earnings per share are expected to be between $5.00 and $5.15 in 2026
80% confidenceMerck expects revenues to be in the range of $65.5-$67.0 billion in 2026, representing year-over-year growth of 1% to 3%
80% confidenceThe adjusted gross margin is expected to be around 82% in 2026
80% confidenceIn 2026, Merck expects to buy back shares worth $3 billion
80% confidenceThe estimate of $70 billion was $20 billion more than its previous estimate a year ago
80% confidenceThe estimate of $70 billion was more than double the peak consensus estimate for Keytruda revenues of $35 billion in 2028
80% confidence